Kinin-generating cascade in advanced cancer patients and in vitro study - PubMed (original) (raw)
Comparative Study
Kinin-generating cascade in advanced cancer patients and in vitro study
Y Matsumura et al. Jpn J Cancer Res. 1991 Jun.
Abstract
The role of the bradykinin-generating system in the pathogenesis of cancer was explored by simultaneously measuring plasma prekallikrein (PK), the precursor of kallikrein, which is the major enzyme responsible for kinin generation, and plasma kininogens (KNG), which are precursors of kinin, in patients with various cancers. The mean value of plasma PK in healthy volunteers was 2.5 +/- 0.5 (mean +/- SD) units/mg plasma protein and that in cancer patients (all stage IV) was 1.7 +/- 0.7 units/mg plasma protein. The mean value of plasma KNG in healthy volunteers was 12.5 +/- 2.0 ng kinin equivalents/mg plasma protein and that in cancer patients was 10.9 +/- 2.8 ng. These data showed that plasma PK and plasma KNG values were significantly lower in cancer patients compared with healthy volunteers (P less than or equal to 0.005 for PK; 0.0005 less than P less than or equal to 0.005 for KNG; n = 28 for healthy subjects; n = 29 for cancer patients). These data appear to indicate that conversion of PK to kallikrein would probably occur with concomitant consumption of KNG by newly generated kallikrein for kinin generation in cancer patients. Early stage cancer patients showed little difference from healthy volunteers. For the in vitro study, activation of purified Hageman factor (HF) and PK was examined by using cancer cell lines and virus-transformed cells that produced plasminogen activator (PA) at a high rate. Both HF and PK were activated in the presence of plasminogen. Diploid cell lines and primary fibroblasts, which did not produce PA, activated neither HF nor PK. Taking all these data together, we conclude that kinin generation does occur in the plasma of patients with advanced cancer, and that one of the initiation mechanisms of the kinin-generating cascade appears to be mediated by plasmin and to depend on cancer cell-derived PA activity.
Similar articles
- Dissemination of contact activation in plasma by plasma kallikrein.
Cochrane CG, Revak SD. Cochrane CG, et al. J Exp Med. 1980 Sep 1;152(3):608-19. doi: 10.1084/jem.152.3.608. J Exp Med. 1980. PMID: 6902742 Free PMC article. - Surface activation of blood coagulation, fibrinolysis and kinin formation.
Heimark RL, Kurachi K, Fujikawa K, Davie EW. Heimark RL, et al. Nature. 1980 Jul 31;286(5772):456-60. doi: 10.1038/286456a0. Nature. 1980. PMID: 6447254 - Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.
Sealey JE, Atlas SA, Laragh JH, Silverberg M, Kaplan AP. Sealey JE, et al. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5914-8. doi: 10.1073/pnas.76.11.5914. Proc Natl Acad Sci U S A. 1979. PMID: 42905 Free PMC article. - Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP, Joseph K. Kaplan AP, et al. Adv Immunol. 2014;121:41-89. doi: 10.1016/B978-0-12-800100-4.00002-7. Adv Immunol. 2014. PMID: 24388213 Review. - The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin-generation.
Kaplan AP, Meier HL, Mandle R Jr. Kaplan AP, et al. Semin Thromb Hemost. 1976 Jul;3(1):1-26. doi: 10.1055/s-0028-1087162. Semin Thromb Hemost. 1976. PMID: 139682 Review. No abstract available.
Cited by
- Diagnostic and prognostic role of circulating neutrophil extracellular trap markers and prekallikrein in patients with high-grade serous ovarian cancer.
Kim JG, Kim SI, Song SH, Gu JY, Lee M, Kim HK. Kim JG, et al. Front Oncol. 2022 Dec 22;12:992056. doi: 10.3389/fonc.2022.992056. eCollection 2022. Front Oncol. 2022. PMID: 36620601 Free PMC article. - Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors.
Islam W, Niidome T, Sawa T. Islam W, et al. J Pers Med. 2022 Nov 28;12(12):1964. doi: 10.3390/jpm12121964. J Pers Med. 2022. PMID: 36556185 Free PMC article. Review. - Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.
Rasel MSI, Mohona FA, Akter W, Kabir S, Chowdhury AA, Chowdhury JA, Hassan MA, Al Mamun A, Ghose DK, Ahmad Z, Khan FS, Bari MF, Rahman MS, Amran MS. Rasel MSI, et al. J Oncol. 2022 Sep 29;2022:9396760. doi: 10.1155/2022/9396760. eCollection 2022. J Oncol. 2022. PMID: 36284633 Free PMC article. Review. - Development of a Selective Tumor-Targeted Drug Delivery System: Hydroxypropyl-Acrylamide Polymer-Conjugated Pirarubicin (P-THP) for Pediatric Solid Tumors.
Makimoto A, Fang J, Maeda H. Makimoto A, et al. Cancers (Basel). 2021 Jul 23;13(15):3698. doi: 10.3390/cancers13153698. Cancers (Basel). 2021. PMID: 34359599 Free PMC article. Review. - The contact system in liver injury.
Rangaswamy C, Mailer RK, Englert H, Konrath S, Renné T. Rangaswamy C, et al. Semin Immunopathol. 2021 Aug;43(4):507-517. doi: 10.1007/s00281-021-00876-7. Epub 2021 Jun 14. Semin Immunopathol. 2021. PMID: 34125270 Free PMC article. Review.
References
- ) Maeda , H. , Takeshita , J. and Kanamaru , R.A lipophilic derivative of neocarzinostatin, A polymer conjugation to an antitumor protein antibiotic . Int. J. Peptide Protein Res. , 14 , 81 – 87 ( 1979. ). - PubMed
- ) Maeda , H. , Matsumura , Y. , Oda , T. and Sasamoto , K.Cancer selective macromolecular therapeusis: tailoring of antitumor protein drugs . In “ Protein‐tailoring for Food and Medical Uses ”, ed. Feeney R. E. and Whitaker J. R. , pp. 353 – 381 ( 1986. ). Marcel Dekker; , New York .
- ) Matsumura , Y. and Maeda , H.A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS . Cancer Res. , 46 , 6387 – 6392 ( 1986. ). - PubMed
- ) Maeda , H. and Matsumura , Y.Tumoritropic and lymphotropic principle of macromolecular drugs . Crit. Rev. Ther. Drug Carrier Sys. , 6 , 193 – 210 ( 1989. ). - PubMed
- ) Konno , T. , Maeda , H. , Iwai , K. , Tashiro , S. , Maki , S. , Morinaga , T. , Mochinaga , M. , Hiraoka , T. and Yokoyama , I.Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report . Eur. J. Cancer Clin. Oncol. , 19 , 1053 – 1065 ( 1984. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous